Jon A. Rowley, PhD, is the Founder & Chief Product Officer of RoosterBio Inc. Jon started RoosterBio in 2013 as part of his personal quest of having the biggest impact possible on the commercial translation of technologies that incorporate living cells, including cellular therapies, engineered tissues, and tomorrow’s medical devices. Jon holds a PhD from the University of Michigan in Biomedical Engineering and has authored over 35 peer reviewed manuscripts and 20 issued or pending patents related to biomaterials development, tissue engineering, and cellular therapy.

Dr. Carson has over 25 years of experience in both academic and commercial biotechnology science research, having focused in areas of technology analysis, strategy, synthetic biology, protein engineering and cell signaling. Prior to joining RoosterBio in January 2020, he was at intrexon Corporation (now Precigen), where he worked in various roles for 12 years. Jonathan completed postdocs at Harvard’s Center for Molecular Imaging Research and at Boston University Medical Center’s Department of Genetics and Genomics. His PhD (Microbiology) is from the University of Virginia, with a thesis related to anti-apoptotic signaling in cancer. LinkedIn: https://www.linkedin.com/in/jonathan-carson-phd/

Jason Bishop joined RoosterBio in 2017 as the Manufacturing Manager, bringing over a decade of experience with cGMP manufacturing and the process development of many Cell Therapies. In January of 2019 Jason transitioned to his current role as Development Services Manager where his skills and experience are helping our customers implement RoosterBio technology to excel in the regenerative medicine industry. Jason holds Bachelor of Science degrees in Marine Science as well as Biology from Coastal Carolina University, and a MS in Biomedical Science from Hood College.

Joseph Takacs, MS, currently operates as a Bioprocessing Application Scientist for RoosterBio. After joining RoosterBio in late 2016, Joseph focused much of his work within the research and development team to help advance RoosterBio's analytical, product, and process developments. In early 2020, Joseph moved to a commercial-facing role to help create a world where safe and effective regenerative medicines are rapidly developed and widely available on a global scale, to benefit the lives of patients in need. LinkedIn: www.linkedin.com/in/josephtakacs

Kathy Williams has provided strategic leadership, direction, and oversight for all quality assurance activities since joining RoosterBio in January 2017 as Director, Quality Assurance. In January 2018, Kathy was promoted to VP of Quality Assurance and Regulatory Affairs. In her expanded role, Kathy is also responsible for providing global regulatory guidance and managing RoosterBio’s biologic master files to support customers’ regulatory submissions. Kathy has extensive GMP industry experience in quality assurance and regulatory compliance. She holds a MS degree from Johns Hopkins University.

John Getz joined RoosterBio in 2018 as the Government Account Manager. John was a key Department of Defense influencer for Warfighter specific medical solutions for 16+ years. His project efforts included regenerative medicine, medical intelligence, extremity injury, prosthetics, assistive and exoskeleton technologies, haptics, proprioception, advanced pharmaceutical systems as well as forensic radiology, advanced injury analysis, weapon, vehicle and personnel protection systems. John is a certified Program Management Defense Acquisition Professional and holds a Bachelor of Science in Biology with emphasis in Chemistry from Millersville University.

In her role at RoosterBio, Josephine Lembong, PhD, was responsible for the design and implementation of new technologies and processes for scalable stem cell manufacturing, as well as providing technical direction in cGMP tech transfer. Prior to joining RoosterBio, Josephine did her post-doctoral fellowship at the University of Maryland, where she worked on bioreactor development for stem cell culture. She received her PhD in Chemical Engineering from Princeton University.

Katrina Adlerz, PhD, was a Senior Scientist at RoosterBio focused on product and process development for innovative products related to MSCs in the fields of Regenerative Medicine, Tissue Engineering, and Cell Therapy. Katrina is a bioengineer by training. She earned her Bachelor of Science in Biomedical Engineering from the University of Virginia, and her PhD in Bioengineering from the University of Maryland.

Dr. Lim is a stem cell bioprocessing veteran with many years of experience developing bioreactor processes and application of experimental design strategies. She has been recognized for her initiative in developing bioprinting tools for education as founder of SE3D and prior to that was an Assistant Professor in Bioengineering at Nanyang Technological University in Singapore, spearheading the stem cell bioprocessing group in bone marrow and cardiac tissue engineering. Dr. Lim obtained her PhD in Chemical Engineering from Imperial College London and supported the West Coast and APAC accounts for RoosterBio for over a year.